Deadly venom from snakes, frogs, scorpions and insects could lead to novel treatments for cardiovascular disease, cancer, and diabetes, thanks to a new toxin library, which can be screened to find leads for new drugs.
While there are already a handful of drugs derived from venom, new research is enabling scientists to more easily analyse how toxins work and reproduce them in a lab.
When a venomous animal bites or stings, the cocktail of toxins that constitute a venom act rapidly in the body. They’ve evolved to be highly specific to particular molecules, binding to them tightly, like a key into a lock. And because of stable cross-links in their structure, toxins aren’t easily broken down by the body.
It is this ability to seek out and bind to specific molecules that makes scientists believe they might be useful in targeting disease.
‘Animal toxins are known to display fabulous pharmacological properties, with high affinity and selectivity,’ said Dr Nicolas Gilles, who coordinates the EU-funded VENOMICS project. ‘And that’s why they represent a very interesting source of drug candidates.’
In order to create a library, or biobank, of different toxins and their properties, VENOMICS researchers have developed new techniques to study the composition and properties of thousands of toxin molecules that make up venom.
They are building on the success of the 2007-2011 CONCO project, also funded by the EU, which identified the active compounds in the venom of a single species of cone snail to create a ‘synthetic library’ of potential drug candidates.
Now, the researchers hope to analyse a whole range of venom samples, most of which have not previously been investigated by science, in order to produce a biobank of brand new drug leads.
‘Animal toxins are known to display fabulous pharmacological properties.’
Dr Nicolas Gilles, CEA, France
‘Previously, it’s been a very slow and costly task to identify the active toxins in a venom, which can be composed of 1 000 different compounds,’ explained Dr Gilles. ‘This is one reason why the pharmaceutical companies so far have hesitated to invest in this field. But now, things are changing.’
The techniques developed by VENOMICS to analyse toxins are faster and more efficient than traditional methods, which require larger volumes of venom and involve gradually breaking it down until the active molecule is isolated – a process than can take up to two years.
In contrast, VENOMICS researchers can scan for useful toxins in a matter of months. Their methods also require 20 times less venom, meaning that the miniscule volumes produced by tiny animals – such as ants and ticks – can finally be studied.
Dr Gilles said: ‘90 % of venomous animals are less than one centimetre in size. Classical technologies are simply not adapted to that scale, making impossible the use of this phenomenal biodiversity.’
173 000 venomous animals
There are 173 000 venomous animals, representing a collection of 40 million molecules of interest. VENOMICS has succeeded in analysing 200 animal species, the largest number of venomous animals ever studied.
A team at the University of Liège, Belgium, was responsible for obtaining the genetic sequences of molecules for analysis, and a Spanish company called Sistemas Genómicos was able to uncover how genes were expressed in venom glands, thanks to the development of original code and new sequencing software.
These two complementary techniques allowed the generation of the biggest databank to date, consisting of 25 000 genetic sequences. From these sequences, 5 000 toxins are now under production by Aix-Marseille University and the CEA Saclay laboratory in France.
The last phase of the project will see scientists conduct screening of the toxin library against specific disease molecules to establish leads for cardiovascular disease, cancer, pain and diabetes drugs.
‘The future of VENOMICS will be the transferring of this technology to private companies,’ said Dr Gilles, ‘transforming our pilot into a larger-scale, industrial project.’
The VENOMICS team aren’t shooting in the dark: a dozen or so major drugs derived from venoms have already made it to market. Here are a few examples:
Captopril: Based on teprotide, sourced from the Brazilian arrowhead viper, this blood vessel relaxing agent is commonly used to treat hypertension.
Tirofiban: First approved in 1998, this anticoagulant was designed to mimic a short sequence found in the venom of the African saw-scaled viper. It’s given to patients recovering from heart attacks, or suffering with angina.
Ziconotide: Chemically identical to a peptide found in cone snail venom, this painkiller (brand name Prialt) can be injected into spinal fluid to stop pain signals reaching the brain.
Tiny pieces of plastic, now ubiquitous in the marine environment, have long been a cause of concern for their ability to absorb toxic substances and potentially penetrate the food chain. Now scientists are beginning to understand the level of threat posed to life, by gauging the extent of marine accumulation and tracking the movement of these contaminants.
Testing the safety of medicines and chemicals on organ-like structures developed from various types of stem cells could reduce the reliance on animal testing and streamline chemical and drug development, according to scientists in the Netherlands who are in the early stages of developing such technology.
The world’s largest radio telescope, known as the Square Kilometre Array (SKA) and situated over two continents, will be able to detect the first stars and galaxies emerging from the ‘murk’ at the beginning of the universe and much more besides, according to Professor Phil Diamond, Director General of SKA. He spoke to Horizon at the opening of the Shared Sky art exhibition in Brussels, Belgium on 16 April, where indigenous artists from SKA host nations South Africa and Australia use traditional painting and folk art to explore the themes of astronomy, spirituality and a borderless sky.
Electric ferries and digital communication between ships could help in the quest to decarbonise maritime transport, a sector which is often perceived as being the green option but could still do much to lower its environmental footprint.
Tiny plastic particles could impact human health.
Astronomers could use giant radio telescope from 2025.
The EU’s research chief on his new role.